IMR Press / FBE / Volume 2 / Issue 1 / DOI: 10.2741/E84

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article

Bing De Ling®, a Chinese herbal formula, inhibits cancer cells growth via p53

Show Less
1 Department of Pathology and Cell Biology, USF College of Medicine
2 Programs of Molecular, Oncology
3 Experimental Therapeutics, H. Lee Moffitt Cancer Center, Tampa, Florida 33612-4799
4 The Center for Traditional Chinese Medicine Inc., 1299 South Tamiami Trail, Sarasota, Florida 34239

*Author to whom correspondence should be addressed.

Academic Editor: Xiaodong Cheng

Front. Biosci. (Elite Ed) 2010, 2(1), 221–230; https://doi.org/10.2741/E84
Published: 1 January 2010
(This article belongs to the Special Issue Cyclic nucleotide signaling and drug discovery)
Abstract

Bing De Ling® is a Chinese herbal formula that has been used to treat cancer patients for more than a decade. However, the molecular mechanisms behind its anti-tumor efficacy are still elusive. Here, we show that Bing De Ling® inhibits cell proliferation in ovarian cancer epithelial cell lines, OV2008 and C13. It induces G1/S arrest in a p53-dependent manner in that this effect is attenuated in OV2008 cells transfected with dominant-negative p53 plasmid. Moreover, we show that Bing De Ling® up-regulates p53 transcriptional activities as well as its downstream target genes, such as p21Cip1, MDM2, and MDMX. In addition, Bing De Ling® inhibits MDMX-p53 interaction which may result in stabilization and activation of p53. Collectively, our results suggest that the anti-tumor activity of Bing De Ling® may be in part due to activation of p53.

Keywords
Ovarian Cancer
p53
Cell Cycle
MDMX
Share
Back to top